Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
VIR has lost 8.5% over the past week and trades at $10.61, yet the options market remains stubbornly bullish and short sellers have pulled back at a pace that stands out even against the last note's already-falling numbers.
The short interest story has moved materially since the October 7 note. Bears held roughly 18.5 million shares then. That figure has dropped to 14.5 million, now 10.4% of the float, a 21% weekly decline and a 28% fall over the past month. The step-down was abrupt: short interest ran between 18 and 19 million shares through the first week of October, then broke lower sharply around October 8. This is a significant cover, not a drift. Borrow conditions confirm the retreat is not borrow-driven. Cost to borrow is 0.40%, down 16% on the week and near its cheapest level of recent months. Availability is very loose at over 1,030% of short interest, meaning there are roughly ten shares available to borrow for every one already lent out. There is no squeeze dynamic at work here. Shorts are choosing to exit.
Options positioning remains the most striking feature of the setup, consistent with last week's read but now even more extreme. The put/call ratio is 0.097, below the 52-week low of 0.036 is still some distance away, but the current reading is 1.7 standard deviations below the 20-day average of 0.154. Call buyers are dominating to an unusual degree, even as the stock is selling off. That divergence between a falling price and a call-heavy options book is the central tension heading into the November 5 earnings date.
The Street remains broadly constructive. HC Wainwright raised its target to $22 from $20 last week, keeping its Buy rating, and that is the freshest analyst action on record. Morgan Stanley and Leerink Partners also lifted targets earlier this year. The consensus mean target is $21, roughly double the current price. The bull case centres on VIR-5500 monotherapy data and the HDV franchise, specifically SOLSTICE data showing HDV RNA target-not-detected reaching 88% at Week 96. The bear case is harder to dismiss: 2026 revenue of around $259 million is projected to collapse to roughly $73 million in 2027 as transaction-driven upfronts roll off, and the company faces expected annual gross equity raises of $300 million to $350 million in 2028 and 2029. EPS momentum scores well on a 90-day basis, ranking in the 89th percentile, but the forward earnings growth rank is in the 11th percentile, reflecting that gap between near-term deal revenue and the longer-term burn.
One ownership detail is worth carrying. Robert Nelsen filed a Schedule 13D/A in March 2026, disclosing an 8.5% activist stake of 13.5 million shares. A 13D filer has stated activist intent, and the position remains on the register as last disclosed. Note the standard caveat: 13D/G positions are disclosed around the 5% threshold, and a holder who drops below 5% may not file again. Separately, BlackRock added nearly 2.7 million shares in the most recent quarter and now holds 12.2% of shares outstanding. State Street also added 2.8 million shares. Institutional accumulation at the index-fund level has been running alongside a stock that has broadly outperformed its sector year-to-date, though that outperformance has been fading in recent weeks. ORTEX's Wikipedia attention tracker logged a z-score of 5.0 as of late September, signalling an unusual spike in retail interest relative to VIR's own 90-day history.
The prior two earnings prints both produced negative one-day moves, down 3.2% and 4.4% respectively, with further weakness over the following week. With the stock already down 8.5% this week ahead of the November 5 release, the setup going into the print is what to watch: whether that aggressive call positioning survives the remaining three weeks, and whether short interest continues to retreat or stabilises around the 10% level.
See the live data behind this article on ORTEX.
Open VIR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
